| First Author | Nicoletti F | Year | 1999 |
| Journal | Immunology | Volume | 97 |
| Issue | 3 | Pages | 367-70 |
| PubMed ID | 10447755 | Mgi Jnum | J:56336 |
| Mgi Id | MGI:1340818 | Doi | 10.1046/j.1365-2567.1999.00836.x |
| Citation | Nicoletti F, et al. (1999) Endogenous interleukin-12 only plays a key pathogenetic role in non-obese diabetic mouse diabetes during the very early stages of the disease. Immunology 97(3):367-70 |
| abstractText | A rat monoclonal antibody (mAb) that neutralizes mouse interleukin-12 (IL-12) was administered to female non-obese diabetic (NOD) mice of different ages to dismantle the role of endogenous IL-12 in murine autoimmune diabetogenesis. This mAb was effective in preventing clinical, but not histological signs of spontaneous diabetes when treatment was started early in life at the age of 4 weeks and consecutively continued for 10 weeks. Delaying commencement of anti-IL-12 mAb prophylaxis until the age of 18 weeks, when NOD mice suffer from advanced insulitis, was ineffective. Anti-IL-12 mAb did not influence the course of the accelerated model of diabetes induced by cyclophosphamide. These data prove that the pathogenetic role of endogenous IL-12 in NOD mouse diabetes is restricted to the very early diabetogenic events presumably occurring prior to insulitis development. |
